Transpulmonary PressureNCT02354365
Measuring Lung Pressures in Critically Ill Children Who Are on Mechanical Ventilation
An observational study of Transpulmonary Pressure and Pressure.Rate Product, run by Children's Hospital Los Angeles at 1 site in United States.
Trial summary
Typically doctors adjust the settings on the ventilator to ensure that children receive enough help to decrease the work they perform to breathe, receive enough oxygen through the machine to pass into the blood and to the organs, and remove acid that builds up in the blood. Read more about this study
- Who is it for?
- Ages 1 week to 18 years
- Conditions the study is for
- Transpulmonary Pressure, Pressure.Rate Product, Guide to Mechanical Ventilator Management
- What is being tested?
- Transpulmonary Pressure measurement
- Type of treatment
- Medical device
- How many people
- 55 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2014to 31 Dec 2024
- How long will I take part?
- 1 Week
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 week to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Any patient weighing >2 kg between the ages of > 37 weeks corrected gestational age and <18 years who is intubated and mechanically ventilated in the pediatric intensive care unit at Children's Hospital Los Angeles will be eligible for the study.
Who may be able to join
- We seek to group patients into 3 potential cohorts:
- Normal Lungs (maximum 30 patients): Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
- AHRF (maximum 15 patients): Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS).
- Obstructive airway disease (15 patients): Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis)
Who cannot join
- Patients with a corrected gestational age of < 37 weeks or above 18 years of age. Patients with esophageal pathology or inability to utilize an esophageal probe due to anatomy, those on a high frequency oscillator or jet ventilator and those with uncorrected or persistent cyanotic congenital heart diseases will be excluded. Also, patients with an endotracheal tube leak of more than 18% or inability to measure volume, pressure or flow at the endotracheal tube will be excluded from the study
Trial locations and contacts
1 site in 1 country.
United States1 site
Children's Hospital Los Angeles
Los Angeles, California, 90027
About this study
Official title: Transpulmonary Pressure Monitoring as a Guide to Ventilator Management
Typically doctors adjust the settings on the ventilator to ensure that children receive enough help to decrease the work they perform to breathe, receive enough oxygen through the machine to pass into the blood and to the organs, and remove acid that builds up in the blood. However, sometimes the settings we choose can result in damage to the lungs. We are trying to find a better way to determine the best ventilator settings, which can minimize potential damage to the lungs, and still provide children with enough support to decrease the work they have to do to breathe. We believe we can personalize these choices for each child by looking at the pressure that is generated in the chest while children breathe with the ventilator. This is accomplished by using a small tube which goes through the nose and into the esophagus or stomach, which is hooked up to a computer or the ventilator to monitor pressure. This same tube can then also be used to monitor how much work children need to do to breathe as we are turning down the ventilator in preparation to remove the breathing tube.
Read the detailed description
Any patient weighing >2 kg between the ages of > 37 weeks corrected gestational age and <18 years who is intubated and mechanically ventilated will be eligible for the study. We seek to group patients into 3 potential cohorts:
- Normal Lungs (maximum 30 patients): Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction). ii. AHRF (maximum 15 patients): Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS). iii. Obstructive airway disease (15 patients): Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
Patients with a corrected gestational age of < 37 weeks or above 18 years of age. Patients with esophageal pathology or inability to utilize an esophageal probe due to anatomy, those on a high frequency oscillator or jet ventilator and those with uncorrected or persistent cyanotic congenital heart diseases will be excluded. Also, patients with an endotracheal tube leak of more than 18% or inability to measure volume, pressure or flow at the endotracheal tube will be excluded from the study.
Participation of this study can last for the duration of mechanical ventilation as pulmonary measurements will be taken during the initial phase as well as during the weaning phase of mechanical ventilation. Once patients are enrolled and informed consents obtained, an esophageal catheter will be inserted and remain in place until after extubation. The available catheters (7 and 16 French) used will be similar to size of feeding tubes used for intubated patients. These catheters/feeding tubes are often used in PICU and NICUs and are FDA 510K approved. There has been published data from our PICU for the use of these catheters in the neonatal population. For neonates and younger patients 2 kg to 10 kg, we will be using the 7Fr catheters. For older patients > 10 kg, we will be using the 16 Fr catheters. Patients that are intubated and not in the study have similar sized feeding catheters (that do not have the manometer function) routinely placed by bedside nursing staff for feeding or temperature monitoring purposes. The esophageal catheters function as both a manometer as well as a feeding tube that stays in place for the duration of mechanical ventilation. The manometer part of the catheter is located at the 1/3 of the catheter while the same catheter's distal port that serves as a feeding tube projects into the stomach. We will limit our placement of the esophageal catheter to three attempts per day. Once it is in optimal position, there will not be a need to re-adjust the catheter for pressure monitor or feeding purposes. The catheter will stay in place for duration of mechanical ventilation. Confirmation of the esophageal catheter placement will be made when the patient obtains a daily chest x-ray for routine clinical care. There will be no additional radiation exposure for intubated patients that are participating in this study than those that are not participating in this study . The esophageal catheter will be connected to the Avea mechanical ventilator and all parts will be check to ensure they are properly functioning. In order to facilitate TPP measurements, patients will need to be well sedated. During routine nursing care, mechanically ventilated patients either receive continuous or bolus sedation medication. We will time the TPP measurements to be done after patient has received bolus sedation medication.
Baseline ventilator settings will be collected. At patients' baseline ventilator settings, cardiac output (CO) will be measured using an ultrasound cardiac output monitor (USCOM). TPP measurements will be obtained at PEEP while performing an expiratory hold on the ventilator. TPP will then be obtained at PIP while performing and inspiratory hold on the ventilator. Once TPP measurements completed, PEEP will be adjusted by 2cm H2O increments to TPP. For every 2cm H2O adjustment on the ventilator, we will observe for patient tolerance of ventilator change for 2 minutes. If patients show any signs of intolerance (decrease SpO2 > 5%, increase in end tidal CO2 by more than 10 torr, heart rate >40 bpm from baseline, clinical respiratory distress), ventilator settings will be returned to baseline. Once PEEP has been adjusted to TPP, CO will be measured again using the USCOM. Measurements (CO, TPP at PEEP, TPP at PIP) will be done three times to ensure reproducibility and an average measurement of the three will be used for data description. TPP measurements will be done daily for up to 7 days. We will discontinue TPP measurements once patients are recovering and entering the weaning phase of mechanical ventilation (this is clinically determined by the primary care team in the PICU). The average length of mechanical ventilation for children in the PICU is 5-6 days, therefore an estimate of the number of TPP measurements will be 5-6 measurements.
For the later part of the study, when patients are consistently breathing spontaneously and have entered the weaning phase of ventilation, the same esophageal catheter used in the first part of the study will be used to measure pressure rate product as a surrogate for work of breathing while patients are trialed on minimal ventilator support. The esophageal catheter will be connected to the Bicore, a device that will monitor pulmonary measurements using the esophageal catheter to obtain pressure rate product measurements. The PRP will be measured with each decrease in setting of minimal ventilator support (starting from pressure support/PEEP of 10/5 cm H20 to 5/5 cm H20 to CPAP of 5cm H20). Patients will be placed on each setting for a 5 minute period and monitored for any signs of intolerance (decrease SpO2 > 5%, increase in end tidal CO2 by more than 10 torr, heart rate >40 bpm from baseline, clinical respiratory distress). Should patients not tolerate the decrease in settings of support, ventilator settings will be returned to baseline prior to changes made.
Analysis will be largely descriptive and provide information for the development of a transpulmonary pressure based protocol for ventilator management. Specifically, we will examine typical differences between PEEP set by clinicians, those recommended by available PEEP/FiO2 titration tables (ARDSNET 2000) and those recommended based on transpulmonary pressure, to determine whether there would be potential differences in choice of PEEP based on the method chosen. We will use the data to explore decision points for peak inspiratory pressure, again comparing differences between airway pressure and alveolar pressure, particularly as PEEP is changed. Finally, for aim 2, we seek to determine the potential decrease in number of days of mechanical ventilation if a minimum effort of breathing was used for the determination of extubation readiness. This will inform power calculations for future studies in which we may consider this endpoint, rather than actual extubation.
- Conditions
- Transpulmonary Pressure, Pressure.Rate Product, Guide to Mechanical Ventilator Management, Extubation Readiness
- Being tested
- Transpulmonary Pressure measurement
- Keywords
- PEEP adjustment, Tidal Volume, Driving Pressure, Compliance
- Medical subject headings
- Patient Compliance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transpulmonary Pressure measurementDevice
Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
| Study group | Role | What they receive |
|---|---|---|
| Normal lungs | Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction). Receives: Device: Transpulmonary Pressure measurement | |
| Acute Hypoxic Respiratory Failure | Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS). Receives: Device: Transpulmonary Pressure measurement | |
| Obstructive airway disease | Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis). Receives: Device: Transpulmonary Pressure measurement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Transpulmonary pressure
Effect of cardiac index of increasing PEEP guided by transpulmonary pressure at PEEP.
Measured: Two years
Secondary outcomes (1)
Pressure rate product (PRP)
Effect on PRP as measure of effort of breathing while weaning on PEEP guided by transpulmonary pressure at PEEP
Measured: Two years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2015 (estimated)
- Study startFeb 2014
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Transpulmonary PressureStudies of the same condition, open and under way.
- More trials run by Children's Hospital Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 55 participants (actual)
- Target duration
- 1 Week
Sponsor and investigators
- Lead sponsor
- Children's Hospital Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christopher J. L. Newth, MD, Children's Hospital Los Angeles
- Investigators
- Christopher Newth, MD, Principal investigator, Children's Hospital Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02354365
- Sponsor's protocol ID
- CCI-13-00370
- Status last verified
- Oct 2023
- First submitted
- 29 Jan 2015
- Last updated
- 15 Feb 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ingaramo OA, Ngo T, Khemani RG, Newth CJ. Impact of positive end-expiratory pressure on cardiac index measured by ultrasound cardiac output monitor*. Pediatr Crit Care Med. 2014 Jan;15(1):15-20. doi: 10.1097/PCC.0b013e3182976251.
PubMed 24389709Ross PA, Khemani RG, Rubin SS, Bhalla AK, Newth CJ. Elevated positive end-expiratory pressure decreases cardiac index in a rhesus monkey model. Front Pediatr. 2014 Dec 3;2:134. doi: 10.3389/fped.2014.00134. eCollection 2014.
PubMed 25520944Hotz JC, Sodetani CT, Van Steenbergen J, Khemani RG, Deakers TW, Newth CJ. Measurements Obtained From Esophageal Balloon Catheters Are Affected by the Esophageal Balloon Filling Volume in Children With ARDS. Respir Care. 2018 Feb;63(2):177-186. doi: 10.4187/respcare.05685. Epub 2017 Oct 31.
PubMed 29089460Virk MK, Hotz JC, Wong W, Khemani RG, Newth CJL, Ross PA. Minimal Change in Cardiac Index With Increasing PEEP in Pediatric Acute Respiratory Distress Syndrome. Front Pediatr. 2019 Jan 29;7:9. doi: 10.3389/fped.2019.00009. eCollection 2019.
PubMed 30761278
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Transpulmonary Pressure Monitoring as a Guide to Ventilator Management
- ClinicalTrials.gov ID
- NCT02354365
- Acronym / sponsor ID
- CCI-13-00370
- Conditions
- Transpulmonary Pressure, Pressure.Rate Product, Guide to Mechanical Ventilator Management, Extubation Readiness
- Keywords
- PEEP adjustment, Tidal Volume, Driving Pressure, Compliance
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 55 participants (actual)
- Lead sponsor
- Children's Hospital Los AngelesUniversity, hospital or other
- Study start
- Feb 2014 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 3 Feb 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Typically doctors adjust the settings on the ventilator to ensure that children receive enough help to decrease the work they perform to breathe, receive enough oxygen through the machine to pass into the blood and to the organs, and remove acid that builds up in the blood. However, sometimes the settings we choose can result in damage to the lungs. We are trying to find a better way to determine the best ventilator settings, which can minimize potential damage to the lungs, and still provide children with enough support to decrease the work they have to do to breathe. We believe we can personalize these choices for each child by looking at the pressure that is generated in the chest while children breathe with the ventilator. This is accomplished by using a small tube which goes through the nose and into the esophagus or stomach, which is hooked up to a computer or the ventilator to monitor pressure. This same tube can then also be used to monitor how much work children need to do to breathe as we are turning down the ventilator in preparation to remove the breathing tube.
Detailed description
Any patient weighing >2 kg between the ages of > 37 weeks corrected gestational age and <18 years who is intubated and mechanically ventilated will be eligible for the study. We seek to group patients into 3 potential cohorts:
- Normal Lungs (maximum 30 patients): Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction). ii. AHRF (maximum 15 patients): Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS). iii. Obstructive airway disease (15 patients): Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
Patients with a corrected gestational age of < 37 weeks or above 18 years of age. Patients with esophageal pathology or inability to utilize an esophageal probe due to anatomy, those on a high frequency oscillator or jet ventilator and those with uncorrected or persistent cyanotic congenital heart diseases will be excluded. Also, patients with an endotracheal tube leak of more than 18% or inability to measure volume, pressure or flow at the endotracheal tube will be excluded from the study.
Participation of this study can last for the duration of mechanical ventilation as pulmonary measurements will be taken during the initial phase as well as during the weaning phase of mechanical ventilation. Once patients are enrolled and informed consents obtained, an esophageal catheter will be inserted and remain in place until after extubation. The available catheters (7 and 16 French) used will be similar to size of feeding tubes used for intubated patients. These catheters/feeding tubes are often used in PICU and NICUs and are FDA 510K approved. There has been published data from our PICU for the use of these catheters in the neonatal population. For neonates and younger patients 2 kg to 10 kg, we will be using the 7Fr catheters. For older patients > 10 kg, we will be using the 16 Fr catheters. Patients that are intubated and not in the study have similar sized feeding catheters (that do not have the manometer function) routinely placed by bedside nursing staff for feeding or temperature monitoring purposes. The esophageal catheters function as both a manometer as well as a feeding tube that stays in place for the duration of mechanical ventilation. The manometer part of the catheter is located at the 1/3 of the catheter while the same catheter's distal port that serves as a feeding tube projects into the stomach. We will limit our placement of the esophageal catheter to three attempts per day. Once it is in optimal position, there will not be a need to re-adjust the catheter for pressure monitor or feeding purposes. The catheter will stay in place for duration of mechanical ventilation. Confirmation of the esophageal catheter placement will be made when the patient obtains a daily chest x-ray for routine clinical care. There will be no additional radiation exposure for intubated patients that are participating in this study than those that are not participating in this study . The esophageal catheter will be connected to the Avea mechanical ventilator and all parts will be check to ensure they are properly functioning. In order to facilitate TPP measurements, patients will need to be well sedated. During routine nursing care, mechanically ventilated patients either receive continuous or bolus sedation medication. We will time the TPP measurements to be done after patient has received bolus sedation medication.
Baseline ventilator settings will be collected. At patients' baseline ventilator settings, cardiac output (CO) will be measured using an ultrasound cardiac output monitor (USCOM). TPP measurements will be obtained at PEEP while performing an expiratory hold on the ventilator. TPP will then be obtained at PIP while performing and inspiratory hold on the ventilator. Once TPP measurements completed, PEEP will be adjusted by 2cm H2O increments to TPP. For every 2cm H2O adjustment on the ventilator, we will observe for patient tolerance of ventilator change for 2 minutes. If patients show any signs of intolerance (decrease SpO2 > 5%, increase in end tidal CO2 by more than 10 torr, heart rate >40 bpm from baseline, clinical respiratory distress), ventilator settings will be returned to baseline. Once PEEP has been adjusted to TPP, CO will be measured again using the USCOM. Measurements (CO, TPP at PEEP, TPP at PIP) will be done three times to ensure reproducibility and an average measurement of the three will be used for data description. TPP measurements will be done daily for up to 7 days. We will discontinue TPP measurements once patients are recovering and entering the weaning phase of mechanical ventilation (this is clinically determined by the primary care team in the PICU). The average length of mechanical ventilation for children in the PICU is 5-6 days, therefore an estimate of the number of TPP measurements will be 5-6 measurements.
For the later part of the study, when patients are consistently breathing spontaneously and have entered the weaning phase of ventilation, the same esophageal catheter used in the first part of the study will be used to measure pressure rate product as a surrogate for work of breathing while patients are trialed on minimal ventilator support. The esophageal catheter will be connected to the Bicore, a device that will monitor pulmonary measurements using the esophageal catheter to obtain pressure rate product measurements. The PRP will be measured with each decrease in setting of minimal ventilator support (starting from pressure support/PEEP of 10/5 cm H20 to 5/5 cm H20 to CPAP of 5cm H20). Patients will be placed on each setting for a 5 minute period and monitored for any signs of intolerance (decrease SpO2 > 5%, increase in end tidal CO2 by more than 10 torr, heart rate >40 bpm from baseline, clinical respiratory distress). Should patients not tolerate the decrease in settings of support, ventilator settings will be returned to baseline prior to changes made.
Analysis will be largely descriptive and provide information for the development of a transpulmonary pressure based protocol for ventilator management. Specifically, we will examine typical differences between PEEP set by clinicians, those recommended by available PEEP/FiO2 titration tables (ARDSNET 2000) and those recommended based on transpulmonary pressure, to determine whether there would be potential differences in choice of PEEP based on the method chosen. We will use the data to explore decision points for peak inspiratory pressure, again comparing differences between airway pressure and alveolar pressure, particularly as PEEP is changed. Finally, for aim 2, we seek to determine the potential decrease in number of days of mechanical ventilation if a minimum effort of breathing was used for the determination of extubation readiness. This will inform power calculations for future studies in which we may consider this endpoint, rather than actual extubation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Week
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Normal lungs | – | Device: Transpulmonary Pressure measurementMechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction). |
| Acute Hypoxic Respiratory Failure | – | Device: Transpulmonary Pressure measurementMechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS). |
| Obstructive airway disease | – | Device: Transpulmonary Pressure measurementMechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis). |
Who may qualify
- Ages
- 1 week to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Any patient weighing >2 kg between the ages of > 37 weeks corrected gestational age and <18 years who is intubated and mechanically ventilated in the pediatric intensive care unit at Children's Hospital Los Angeles will be eligible for the study.
Key inclusion criteria (4 listed)
- Normal Lungs (maximum 30 patients): Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
- AHRF (maximum 15 patients): Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS).
- Obstructive airway disease (15 patients): Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis)
Key exclusion criteria (1 listed)
- Patients with a corrected gestational age of < 37 weeks or above 18 years of age. Patients with esophageal pathology or inability to utilize an esophageal probe due to anatomy, those on a high frequency oscillator or jet ventilator and those with uncorrected or persistent cyanotic congenital heart diseases will be excluded. Also, patients with an endotracheal tube leak of more than 18% or inability to measure volume, pressure or flow at the endotracheal tube will be excluded from the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transpulmonary Pressure measurementTranspulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli. | Device | Acute Hypoxic Respiratory Failure, Normal lungs, Obstructive airway disease |
Primary outcome
Transpulmonary pressure
Time frame: Two years
Effect of cardiac index of increasing PEEP guided by transpulmonary pressure at PEEP.
1 secondary outcome
Pressure rate product (PRP)
Time frame: Two years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2024.
- Background: PubMed 24389709Ingaramo OA, Ngo T, Khemani RG, Newth CJ. Impact of positive end-expiratory pressure on cardiac index measured by ultrasound cardiac output monitor*. Pediatr Crit Care Med. 2014 Jan;15(1):15-20. doi: 10.1097/PCC.0b013e3182976251.
- Background: PubMed 25520944Ross PA, Khemani RG, Rubin SS, Bhalla AK, Newth CJ. Elevated positive end-expiratory pressure decreases cardiac index in a rhesus monkey model. Front Pediatr. 2014 Dec 3;2:134. doi: 10.3389/fped.2014.00134. eCollection 2014.
- Background: PubMed 29089460Hotz JC, Sodetani CT, Van Steenbergen J, Khemani RG, Deakers TW, Newth CJ. Measurements Obtained From Esophageal Balloon Catheters Are Affected by the Esophageal Balloon Filling Volume in Children With ARDS. Respir Care. 2018 Feb;63(2):177-186. doi: 10.4187/respcare.05685. Epub 2017 Oct 31.
- Results publication: PubMed 30761278Virk MK, Hotz JC, Wong W, Khemani RG, Newth CJL, Ross PA. Minimal Change in Cardiac Index With Increasing PEEP in Pediatric Acute Respiratory Distress Syndrome. Front Pediatr. 2019 Jan 29;7:9. doi: 10.3389/fped.2019.00009. eCollection 2019.
- Individual participant dataSharing planned: No
Related trials for Transpulmonary Pressure
Recruiting
Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS
ARDS (Moderate or Severe)
Not yet recruiting
A Study of the Determinants of Neurological Outcomes in Patients With Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS), s100b
RecruitingPhase 3
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome, Respiratory Failure
RecruitingObservational study
Effects of AbClo Fascial Approximation Device in Patients With Open Abdomen on Respiratory Mechanics
Open Abdomen, Mechanical Ventilation
Recruiting
Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study.
ARDS, Human, Obesity, Morbid
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christopher Newth, MD principal investigator
Children's Hospital Los Angeles
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Transpulmonary Pressure and Pressure.Rate Product, run by Children's Hospital Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Transpulmonary pressure (time frame: Two years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02354365, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2024.